Vav-1 expression correlates with NFκB activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines

Hematological Oncology

Volumn 28, Issue 3, 2010, Pages 142-150

  Hollmann, Annette ^a   Aloyz, Raquel ^a   Baker, Kristi ^b   Dirnhofer, Stephan ^c   Owens, Trevor ^d   Sladek, Robert ^e   Tzankov, Alexandar ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

CD40 antigen; Diffuse; Gene expression profiling; Immunohistochemistry; Large B cell; Lymphoma; NF B; Proto oncogene proteins c Vav

Indexed keywords

ANTIBODY; CD40 ANTIBODY; CD40 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; KI 67 ANTIGEN; UNCLASSIFIED DRUG; VAV 1 PROTEIN; VAV PROTEIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; MESSENGER RNA; VAV1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL DEATH; DISEASE MARKER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; BIOSYNTHESIS; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE;

AGED; ANTIGENS, CD40; CELL DEATH; CELL LINE, TUMOR; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTORS; KI-67 ANTIGEN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NF-KAPPA B; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-VAV; RNA, MESSENGER;

EID: 77957309180     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.935     Document Type: Article

References (45)

1. Mitterlechner T, Fiegl M, Muhlbock H, Oberaigner W, Dirnhofer S, Tzankov A. Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. J Clin Pathol 2006; 59: 48-55.
2. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004; 23: 6524-6534.
3. Gascoyne RD. Emerging prognostic factors in diffuse large B cell lymphoma. Curr Opin Oncol 2004; 16: 436-441. (Pubitemid 39159170)
4. Hollmann CA, Owens T, Nalbantoglu J, Hudson TJ, Sladek R. Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40- mediated cell death. Cancer Res 2006; 66: 3550-3557.
5. Gruss HJ, Herrmann F, Gattei V, Gloghini A, Pinto A, Carbone A. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk Lymphoma 1997; 24: 393-422. (Pubitemid 27182198)
6. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
7. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
8. Moschese V, Orlandi P, Di Matteo G, et al. Insight into B cell development and differentiation. Acta Paediatr Suppl 2004; 93: 48-51.
9. Hollmann AC, Gong Q, Owens T. CD40-mediated apoptosis in murine B-lymphoma lines containing mutated p53. Exp Cell Res 2002; 280: 201-211. (Pubitemid 35333762)
10. Benoit NE, Wade WF. Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin. Immunopharmacology 1996; 35: 129-139.
11. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003; 10: 1-13. (Pubitemid 36222071)
12. Uckun FM, Gajl-Peczalska K, Myers DE, Jaszcz W, Haissig S, Ledbetter JA. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 1990; 76: 2449-2456.
13. Kelley SK, Gelzleichter T, Xie D, et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 2006; 148: 1116-1123. (Pubitemid 44223017)
14. Law CL, Gordon KA, Collier J, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005; 65: 8331-8338. (Pubitemid 41330598)
15. National Institutes of Health. www.clinicaltrials.gov, Accessed 27 March 2009.
16. Costello RT, Gastaut JA, Olive D. What is the real role of CD40 in cancer immunotherapy? Immunol Today 1999; 20: 488-493.
17. Berberich I, Shu GL, Clark EA. Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol 1994; 153: 4357-4366. (Pubitemid 24346830)
18. Gerondakis S, Strasser A. The role of Rel/NF-kappaB transcription factors in B lymphocyte survival. Semin Immunol 2003; 15: 159-166. (Pubitemid 38155822)
19. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006; 13: 738-747.
20. Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S. NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 2004; 18: 11-17. (Pubitemid 38159433)
21. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 2004; 382: 393-409. (Pubitemid 39243905)
22. Jost PJ, Ruland J. Aberrant NFκB signaling in lymphoma: mechanisms, consequences and therapeutic implications. Blood 2007; 109: 2700-2707.
23. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18: 6938-6947.
24. Tweeddale M, Jamal N, Nguyen A, Wang XH, Minden MD, Messner HA. Production of growth factors by malignant lymphoma cell lines. Blood 1989; 74: 572-578. (Pubitemid 19208795)
25. Epstein AL, Levy R, Kim H, Henle W, Henle G, Kaplan HS. Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer 1978; 42: 2379-2391.
26. Clark EA, Yip TC, Ledbetter JA, et al. CDw40 and BLCaspecific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes. Eur J Immunol 1988; 18: 451-457.
27. Blazejczyk M, Miron M, Nadon R. FlexArray: a statistical data analysis software for gene expression microarrays. Genome Quebec 2007; Montreal, Canada, http://genomequebec.mcgill.ca/FlexArray.
28. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34: 374-378. (Pubitemid 36184095)
29. Tzankov A, Gschwendtner A, Augustin F, et al. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. Clin Cancer Res 2006; 12: 2125-2132.
30. Tzankov A, Heiss S, Ebner S, et al. Angiogenesis in nodal B-Cell lymphomas: a high throughput study. J Clin Pathol 2007; 60: 476-482. (Pubitemid 46867154)
31. Zimpfer A, Went P, Tzankov A, et al. Rare expression of KIT (CD117) in lymphomas: a tissue microarray study of 1166 cases. Histopathology 2004; 45: 398-404.
32. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
33. Lugli A, Zlobec I, Minoo P, et al. Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal-regulated kinase, and phosphorylated AKT in colorectal cancer-a tissue microarray-based approach. Hum Pathol 2006; 37: 1022-1031.
34. Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 2009; doi: 10.3109/10428190903370338.
35. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991-9996.
36. Donze O, Deng J, Curran J, Sladek R, Picard D, Sonenberg N. The protein kinase PKR: a molecular clock that sequentially activates survival and death programs. EMBO J 2004; 23: 564-571.
37. Vigorito E, Gambardella L, Colucci F, McAdam S, Turner M. Vav proteins regulate peripheral B-cell survival. Blood 2005; 106: 2391-2398.
38. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
39. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008; 26: 4587-4594.
40. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-1874.
41. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B cell lymphoma. Blood 2009; 113: 6069-6076.
42. Lenz G, Nagel I, Siebert R, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 2007; 204: 633-643.
43. Zarnegar B, He JQ, Oganesyan G, Hoffmann A, Baltimore D, Cheng G. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci USA 2004; 101: 8108-8113.
44. Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003; 63: 1059-1066.
45. Shringarpure R, Catley L, Bhole D, et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006; 134: 145-156.